Proteomics for drug target discovery
Johan Gottfries(AstraZeneca (Sweden)), Kaj Blennow(Sahlgrenska University Hospital), Björn Holmberg(Sahlgrenska University Hospital), Lars Rosengren(Sahlgrenska University Hospital), Pia Davidsson(AstraZeneca (South Korea)), Magnus Sjögren(Karolinska Institutet)
Cited by 19
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k